Abstract
The discovery that antiphospholipid antibodies recognize plasma proteins that bind to phospholipids rather than recognizing phospholipids themselves has been a major advance in research into antiphospholipid syndrome (APS). It is now established that β2-glycoprotein I (β2 GPI) is the most important antigen for antiphospholipid antibodies. However, the possible pathologic mechanism is still much debated. This is mainly because not all patients with anti-β2 GPI antibodies show clinical symptoms that are related to APS. Several reports indicate that anti-β2 GPI antibodies with lupus anticoagulant (LA) activity are clinically of much importance. Most patients with LA caused by anti-β2 GPI antibodies suffer from thrombosis as a result of recognition of the first domain of β2 GPI by these antibodies. In the search for a pathologic mechanism that might explain the high occurrence of thrombosis in patients with anti-domain I antibodies (LA-causing anti-β2 GPI antibodies), it was found that these antibodies show increased resistance to the anticoagulant activity of annexin A5. We have shown that the same population of antibodies also displays increased resistance to activated protein C. Owing to the diversity of clinical symptoms related to APS, it is likely that other pathologic mechanisms also contribute to the occurrence of APS-related symptoms.
Key Points
-
Current assays to detect antiphospholipid antibodies are not specific enough to predict thrombosis and pregnancy morbidity
-
Lupus anticoagulant activity correlates best with clinical symptoms in antiphospholipid syndrome
-
The main cofactor in antiphospholipid syndrome is β2-glycoprotein I (β2 GPI)
-
Only anti-β2 GPI antibodies directed against domain I of β2 GPI (anti-domain I antibodies) are clinically relevant
-
Anti-domain I antibodies have multiple actions on hemostasis; further research is required to characterize these actions
-
More research is needed to find other populations of antiphospholipid antibodies that are also clinically relevant
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Levine JS et al. (2002) The antiphospholipid syndrome. N Engl J Med 346: 752–763
Galli M et al. (2003) Anti-β2-glycoprotein I and anti-prothrombin antibodies and the risk of thrombosis in the antiphospholipid syndrome. Blood 102: 2717–2723
Galli M et al. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827–1832
Wasserman A et al. (1906) Eine serodiagnostiche reaction bei syphilis [German]. Dtsch Med Wochenschr 32: 745
Pangborn MC (1941) A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 48: 484–486
Moore JE and Mohr GF (1952) Biologically false positive tests for syphilis: type, incidence, and cause. J Am Med Association 150: 467–473
Moore JE and Lutz WB (1955) Natural history of systemic lupus erythematosus: approach to its study through chromic biological false positive reactors. J Chronic Dis 1: 297–316
Conley CL and Hartman RCA (1952) A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 31: 621–622
Beaumont JL (1954) Syndrome hemorrhagic acquis du a un anticoagulant [French]. Sang 25: 1–5
Bowie EJW et al. (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 62: 416–430
Galli M et al. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335: 1544–1547
Matsuura H et al. (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336: 117–118
McNeil HD et al. (1990) Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87: 4120–4124
Bevers EM et al. (1991) Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 66: 629–632
De Laat B et al. (2004) β2-glycoprotein I, playmaker in the antiphospholipid syndrome. Clin Immunol 112: 161–168
Wilson WA et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42: 1309–1311
Miyakis S et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295–306
Consigny PH et al. (2002) High prevalence of co-factor independent anticardiolipin antibodies in malaria exposed individuals. Clin Exp Immunol 127: 158–164
Abuaf N et al. (1997) Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 77: 856–861
Uhtman IW et al. (2002) Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 31: 256–263
De Laat B et al. (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC and their presence correlates strongly with thrombosis. Blood 105: 1540–1545
Opatrny L et al. (2006) Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 33: 2214–2221
De Laat HB et al. (2004) β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104: 3598–3602
Pengo V et al. (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 93: 1147–1152
Devreese KM (2007) A functional coagulation test to identify anti-β2-glycoprotein I dependent lupus anticoagulants. Thromb Res 119: 753–759
Pengo V (2004) A two-step coagulation test to identify antiβ-glycoprotein I lupus anticoagulants. J Thromb Haemost 2: 702–707
Cervera R et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46: 1019–1027
Yang CD et al. (1998) Detection of anti-recombinant β2-glycoprotein I fifth-domain antibodies in sera from patients with systemic lupus erythematosus. Rheumatol Int 18: 5–10
Igarashi M et al. (1996) Human β2-glycoprotein I as an anticardiolipin cofactor determined using mutants expressed by a baculovirus system. Blood 87: 3262–3270
George J et al. (1998) Target recognition of β2-glycoprotein I (β2GPI)-dependent anticardiolipin antibodies: evidence for involvement of the fourth domain of β2GPI in antibody binding. J Immunol 160: 3917–3923
McNeely PA et al. (2001) β2-glycoprotein I-dependent anticardiolipin antibodies preferentially bind the amino terminal domain of β2-glycoprotein I. Thromb Haemost 86: 590–595
Reddel SW et al. (2000) Epitope studies with anti-β2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 15: 91–96
Iverson GM et al. (1998) Anti-β2-glycoprotein I (β2GPI) autoantibodies recognize an epitope on the first domain of β2GPI. Proc Natl Acad Sci USA 95: 15542–15546
Iverson GM et al. (2002) Use of single point mutations in domain I of β2GPI to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 169: 7097–7103
Blank M et al. (1999) Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA 96: 5164–5168
Giannakopoulos B et al. (2007) Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 109: 422–430
Rand JH et al. (1997) Pregnancy loss in the antiphospholipid-antibody syndrome—a possible thrombogenic mechanism. N Engl J Med 337: 154–160
Rand JH et al. (2004) Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. Blood 104: 2783–2790
De Laat B et al. (2007) Correlation between antiphospholipid antibodies that recognize domain I of β2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 109: 1490–1494
Gardiner C et al. (2006) Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 17: 477–483
Nojima J et al. (2005) Acquired activated protein C resistance associated with IgG antibodies against β2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clin Chem 51: 545–552
De Laat B. et al. (2007) Correlation between the potency of a β2-glycoprotein I dependent lupus anticoagulant and the level of resistance to activated protein C [abstract]. Abstract P-S-539, XXIst congress of the ISTH, Geneva
van Lummel M et al. (2005) The binding site in β2-glycoprotein I for ApoER2' on platelets is located in domain V. J Biol Chem 280: 36729–36736
Pennings MT et al. (2007) Platelets express three different splice variants of ApoER2 that are all involved in signalling. J Thromb Haemost 5: 1538–1544
Urbanus RT et al. (2007) Current insight into diagnostics and pathophysiology of the antiphospholipid syndrome. Blood Rev [doi:10.1016/j.blre.2007.09.001]
Hulstein JJ et al. (2007) β2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 110: 1483–1491
Pittoni V and Valesini G (2002) The clearance of apoptotic cells: implications for autoimmunity. Autoimmun Rev 1: 154–161
Acknowledgements
Désirée Lie, University of California, Irvine, CA, is the author of and is solely responsible for the content of the learning objectives, questions and answers of the Medscape-accredited continuing medical education activity associated with this article.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
de Laat, B., Mertens, K. & de Groot, P. Mechanisms of Disease: antiphospholipid antibodies—from clinical association to pathologic mechanism. Nat Rev Rheumatol 4, 192–199 (2008). https://doi.org/10.1038/ncprheum0740
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0740
This article is cited by
-
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Investigational New Drugs (2023)
-
Neurologic Manifestations of the Antiphospholipid Syndrome — an Update
Current Neurology and Neuroscience Reports (2021)
-
Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology
Inflammation Research (2020)
-
Prevention of Stroke in Rheumatoid Arthritis
Current Neurology and Neuroscience Reports (2015)
-
Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I
Immunologic Research (2015)